In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer's Increasingly Specialist Focus

Executive Summary

Pfizer's brand-new oncology business unit appears to be the linchpin in its transformation from primary care behemoth to specialty powerhouse. The Big Pharma also followed this up with the announcement that it was cutting early-stage R&D programs focused on obesity, bone health, and what has been its mainstay--cardiovascular disease. Together, these moves should be viewed as the most extreme example of the industry's flight from primary care medicine into the safer haven of specialty-focused pharmaceuticals,

You may also be interested in...



Novartis Rejiggers Pharma To Favor Oncology

The Swiss pharma changes the leadership structure of its pharmaceutical division in an effort to emphasize oncology; AstraZeneca's Paul Hudson takes over the non-oncology pharma group as David Epstein leaves the company.

Xalkori And The Art Of Modern Drug Development

Pfizer developed crizotinib and its companion diagnostic in just four years after identifying an aberrant ALK gene as the target, spanning a corporate restructuring, the Wyeth integration, and the departure of senior staff in the R&D organization and oncology BU. The next year or so will tell whether Xalkori was a flash in the pan, or whether it marks the long awaited turnaround for Pfizer’s oncology business and a model for nimble drug development.

Despite Recent Setbacks At Pfizer, R&D Chief Is Optimistic About R&D Innovation

Mikael Dolsten cites Pfizer's latest efforts to be more efficient, improve R&D productivity, and implement precision medicine as key to its rebound.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

IV003038

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel